导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.39% | 2099/4773 |
| 近一周 | -1.99% | 1030/5462 |
| 近一月 | -3.72% | 1922/5421 |
| 近一季 | -6.29% | 2036/5209 |
| 近半年 | -1.58% | 1640/4920 |
| 近一年 | 2.89% | 2030/4366 |
| 近两年 | 50.38% | 1451/2954 |
| 近三年 | 31.61% | 986/2253 |
| 成立以来 | 78.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.07% 3024/4961 |
13.26% 2039/5312 |
- - |
- - |
| 2025 | 20.29% 2134/4813 |
-0.69% 2362/3635 |
1.72% 2209/4076 |
18.56% 2282/4524 |
0.44% 1994/4813 |
| 2024 | 16.12% 847/3463 |
2.51% 764/2808 |
-1.39% 1055/3014 |
16.34% 1481/3129 |
-1.26% 1637/3463 |
| 2023 | -9.17% 1119/2656 |
3.79% 1125/2280 |
-4.48% 1189/2385 |
-2.75% 741/2515 |
-5.79% 1502/2655 |
| 2022 | -18.00% 648/2207 |
-14.08% 900/1919 |
7.23% 507/2016 |
-12.33% 695/2113 |
1.52% 1236/2208 |
| 2021 | 4.71% 566/1822 |
-3.05% 749/1255 |
8.93% 599/1330 |
-2.93% 603/1466 |
2.15% 683/1822 |
| 2020 | 35.32% 418/1250 |
-6.19% 466/1028 |
15.63% 481/1067 |
9.66% 634/1164 |
13.76% 333/1184 |
| 2019 | 38.18% 314/1092 |
25.00% 483/754 |
-0.09% 216/804 |
2.70% 289/850 |
7.73% 403/918 |
| 2018 | -22.87% 262/834 |
- - |
- - |
- - |
-11.07% 246/691 |
| 2017 | 17.86% 216/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.51% 246/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| MSCI中国A股国际通联接A VS. 长安沪深300非周期A(740101) |